Kolon Life may have known about Invossa issue earlierKolon Life Science made an announcement Friday suggesting that its Kolon TissueGene subsidiary had been aware that an undisclosed material was used in the making of Invossa.
Kolon has been insisting it was only in February that it learned Invossa - a gene therapy drug for knee osteoarthritis - was made using cell lines not approved by the Ministry of Food and Drug Safety.
But Kolon last week admitted that Kolon TissueGene, which developed Invossa, had known since a test in 2017.
The subsidiary in March 2017 received a test result on Invossa from Lonza, a contract manufacturing firm. Invossa has two cells: pure cartilage cells and cartilage cells with genes that foster growth. The controversy erupted in February after it was revealed that another type of cell was used and not disclosed. Invossa has been injected more than 3,000 times in Korea since it was commercialized in July 2017.
By Jin Min-ji